Emerging treatments for irritable bowel syndrome

Joseph Ahn, Eli D. Ehrenpreis

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Irritable bowel syndrome (IBS) is a functional GI disorder that is associated with abdominal discomfort and altered bowel habits. It accounts for up to 28% of patients presenting to a gastroenterology practice and poses a significant personal, societal and economic burden internationally. The Manning, Rome I and Rome II criteria were developed to identify appropriate IBS patients for entry into IBS studies in a consistent manner. Refinements in the understanding of the physiology of the enteric nervous system (ENS), which controls motility, secretion and sensation, provided the basis for our comprehension of the pathophysiology of IBS. Visceral hypersensitivity and neurotransmitter imbalance currently receive the most attention as possible mechanisms of IBS. This article outlines conventional treatments and reviews the data on emerging and experimental therapies for IBS. Emerging therapies for IBS using 5-HT mediation include 5-HT3 antagonists, such as ondasetron, granisetron and alosetron, as well as 5-HT4 agonists such as tegaserod and prucalopride. In addition to opioid agonists (e.g. fedotozine) several other drugs that act on other ENS receptors are being studied. In spite of significant progress in IBS research, these emerging therapies require more studies before they can be utilised as clinical treatments.

Original languageEnglish (US)
Pages (from-to)9-21
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
Enteric Nervous System
prucalopride
Therapeutics
Serotonin 5-HT4 Receptor Agonists
Granisetron
Serotonin 5-HT3 Receptor Antagonists
Investigational Therapies
Gastroenterology
Opioid Analgesics
Habits
Neurotransmitter Agents
Serotonin
Hypersensitivity
Economics
Research
Pharmaceutical Preparations

Keywords

  • 5-HT
  • Abdominal pain
  • Alosetron
  • Constipation
  • Diarrhoea
  • Fedotozine
  • Irritable bowel syndrome
  • Tegaserod
  • Visceral sensitivity

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Emerging treatments for irritable bowel syndrome. / Ahn, Joseph; Ehrenpreis, Eli D.

In: Expert Opinion on Pharmacotherapy, Vol. 3, No. 1, 2002, p. 9-21.

Research output: Contribution to journalArticle

Ahn, Joseph ; Ehrenpreis, Eli D. / Emerging treatments for irritable bowel syndrome. In: Expert Opinion on Pharmacotherapy. 2002 ; Vol. 3, No. 1. pp. 9-21.
@article{cb255d8c03464cec917d96316de4dae5,
title = "Emerging treatments for irritable bowel syndrome",
abstract = "Irritable bowel syndrome (IBS) is a functional GI disorder that is associated with abdominal discomfort and altered bowel habits. It accounts for up to 28{\%} of patients presenting to a gastroenterology practice and poses a significant personal, societal and economic burden internationally. The Manning, Rome I and Rome II criteria were developed to identify appropriate IBS patients for entry into IBS studies in a consistent manner. Refinements in the understanding of the physiology of the enteric nervous system (ENS), which controls motility, secretion and sensation, provided the basis for our comprehension of the pathophysiology of IBS. Visceral hypersensitivity and neurotransmitter imbalance currently receive the most attention as possible mechanisms of IBS. This article outlines conventional treatments and reviews the data on emerging and experimental therapies for IBS. Emerging therapies for IBS using 5-HT mediation include 5-HT3 antagonists, such as ondasetron, granisetron and alosetron, as well as 5-HT4 agonists such as tegaserod and prucalopride. In addition to opioid agonists (e.g. fedotozine) several other drugs that act on other ENS receptors are being studied. In spite of significant progress in IBS research, these emerging therapies require more studies before they can be utilised as clinical treatments.",
keywords = "5-HT, Abdominal pain, Alosetron, Constipation, Diarrhoea, Fedotozine, Irritable bowel syndrome, Tegaserod, Visceral sensitivity",
author = "Joseph Ahn and Ehrenpreis, {Eli D.}",
year = "2002",
doi = "10.1517/14656566.3.1.9",
language = "English (US)",
volume = "3",
pages = "9--21",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Emerging treatments for irritable bowel syndrome

AU - Ahn, Joseph

AU - Ehrenpreis, Eli D.

PY - 2002

Y1 - 2002

N2 - Irritable bowel syndrome (IBS) is a functional GI disorder that is associated with abdominal discomfort and altered bowel habits. It accounts for up to 28% of patients presenting to a gastroenterology practice and poses a significant personal, societal and economic burden internationally. The Manning, Rome I and Rome II criteria were developed to identify appropriate IBS patients for entry into IBS studies in a consistent manner. Refinements in the understanding of the physiology of the enteric nervous system (ENS), which controls motility, secretion and sensation, provided the basis for our comprehension of the pathophysiology of IBS. Visceral hypersensitivity and neurotransmitter imbalance currently receive the most attention as possible mechanisms of IBS. This article outlines conventional treatments and reviews the data on emerging and experimental therapies for IBS. Emerging therapies for IBS using 5-HT mediation include 5-HT3 antagonists, such as ondasetron, granisetron and alosetron, as well as 5-HT4 agonists such as tegaserod and prucalopride. In addition to opioid agonists (e.g. fedotozine) several other drugs that act on other ENS receptors are being studied. In spite of significant progress in IBS research, these emerging therapies require more studies before they can be utilised as clinical treatments.

AB - Irritable bowel syndrome (IBS) is a functional GI disorder that is associated with abdominal discomfort and altered bowel habits. It accounts for up to 28% of patients presenting to a gastroenterology practice and poses a significant personal, societal and economic burden internationally. The Manning, Rome I and Rome II criteria were developed to identify appropriate IBS patients for entry into IBS studies in a consistent manner. Refinements in the understanding of the physiology of the enteric nervous system (ENS), which controls motility, secretion and sensation, provided the basis for our comprehension of the pathophysiology of IBS. Visceral hypersensitivity and neurotransmitter imbalance currently receive the most attention as possible mechanisms of IBS. This article outlines conventional treatments and reviews the data on emerging and experimental therapies for IBS. Emerging therapies for IBS using 5-HT mediation include 5-HT3 antagonists, such as ondasetron, granisetron and alosetron, as well as 5-HT4 agonists such as tegaserod and prucalopride. In addition to opioid agonists (e.g. fedotozine) several other drugs that act on other ENS receptors are being studied. In spite of significant progress in IBS research, these emerging therapies require more studies before they can be utilised as clinical treatments.

KW - 5-HT

KW - Abdominal pain

KW - Alosetron

KW - Constipation

KW - Diarrhoea

KW - Fedotozine

KW - Irritable bowel syndrome

KW - Tegaserod

KW - Visceral sensitivity

UR - http://www.scopus.com/inward/record.url?scp=0036310557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036310557&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.1.9

DO - 10.1517/14656566.3.1.9

M3 - Article

C2 - 11772329

AN - SCOPUS:0036310557

VL - 3

SP - 9

EP - 21

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -